Arcutis Biotherapeutics, Inc.

ARQT Healthcare Biotechnology

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

28.82 0.28 −0.96%
Market cap
$3.7B
P/E
131×
Fwd P/E
196×
Dividend yield
—
F-score
4/9
Altman Z
6.98
Beneish M
−1.52
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 119.18
P/S ratio
7.57 9.82 7.33 7.38
P/FCF ratio
0.00 0.00 269.53 142.16
P/Operating CF
(1,371.55) 141.11 1,361.25 270.77
P/B ratio
15.22 19.50 16.07 15.52
EV/Sales
7.31 9.53 7.06 7.10
EV/EBITDA
0.00 0.00 724.90 92.59
EV/FCF
(48.15) (168.11) 259.37 136.76
Current Ratio
3.50 3.17 2.68 2.92
Net Debt/EBITDA
(9.71) (5.92) 13.19 (7.75)
Debt/Equity
0.69 0.58 0.58 0.49
Earnings Yield
(1.91%) (0.45%) (0.08%) 0.84%
Free Cash Flow Yield
(2.01%) (0.58%) 0.37% 0.70%
Free Cash Flow per Share
(0.01) 0.21 0.02 0.10
Book value per Share
1.24 1.49 1.47 1.69
Free Cash Flow
(1.75) 26.19 2.24 12.48
EV/EBIT
0.00 0.00 912.84 96.12
Other line items

Show all line items

Columns are period end dates